DATE: SEPTEMBER 30, 2020
TIME: 8:00 AM PDT | 11:00 AM EDT
Dr. Fred Beasley provides an overview of study design, criteria for defining your study aim and expert advice for selecting the ideal rodent model for your preclinical obesity research.
During this presentation, Dr. Fred Beasley will give a broad-level overview of the factors to consider when deciding on an appropriate preclinical rodent model for studying obesity and its treatments. It will feature an overview of trends in obesity and associated illnesses, and the role of pharmacological intervention. Dr. Beasley will discuss criteria for establishing a study’s aims and review commonly used rodent models obesity, addressing both genetically inherited and diet-induced animal models. The webinar will conclude with additional considerations for improving your study design.
Key topics will include…
- An introduction to the role of pharmacological intervention in treating obesity
- A guide to establishing study aims for obesity research
- An overview of commonly used rodent obesity models (diet and genetic)
- Additional considerations for obesity research study design
Key methods reviewed will include…
Pharmacotherapy, diet induced obesity, Western-style diet, monogenic obese rodents, polygenic obese rodents, NAFLD activity score
About the Presenter:
Fred Beasley, PhD
Director of Scientific Engagement,
Cardiovascular and Metabolic Disease,
As Director of Scientific Engagement for the Cardiovascular and Metabolic Disease Division at Crown Bioscience, Dr. Fred Beasley has extensive experience with the development of animal models, the design and execution of research projects and with client/operations communications.
Before he was with CrownBio, Fred served as in vivo biologist at the NASH/inflammation startup Jecure Therapeutics and as a Study Director at BTS Research, Southern California’s sole provider of preclinical NHP models.
Fred obtained his PhD in Microbiology and Immunology at the University of Western Ontario and completed postdoctoral training at UC San Diego and at Calibr/Scripps Research Institute. His research focus is the development of animal models to evaluate small molecule drugs against bacterial and parasitic pathogens, and he is an author on over 20 publications.